Evoke Pharma (EVOK)
(Delayed Data from NSDQ)
$0.46 USD
+0.02 (5.05%)
Updated Apr 26, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Evoke Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5 | 3 | 2 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 5 | 2 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 12 | 10 | 9 | 13 | 7 |
Income After Depreciation & Amortization | -7 | -8 | -8 | -13 | -7 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 1 | 1 | 1 | 0 | 0 |
Pretax Income | -8 | -8 | -9 | -13 | -7 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -8 | -9 | -13 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -8 | -9 | -13 | -7 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -7 | -8 | -8 | -13 | -7 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -7 | -8 | -8 | -13 | -7 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.34 | 3.14 | 2.68 | 2.12 | 1.86 |
Diluted EPS Before Non-Recurring Items | -2.33 | -2.62 | -3.24 | -6.24 | -3.84 |
Diluted Net EPS (GAAP) | -2.33 | -2.62 | -3.24 | -6.24 | -3.84 |
Fiscal Year end for Evoke Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.68 | 1.56 | 1.13 | 0.81 |
Cost Of Goods | NA | 0.06 | 0.03 | 0.06 | 0.05 |
Gross Profit | NA | 1.62 | 1.53 | 1.07 | 0.76 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.50 | 3.13 | 2.86 | 2.92 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.88 | -1.60 | -1.79 | -2.16 |
Non-Operating Income | NA | 0.03 | 0.04 | 0.04 | 0.04 |
Interest Expense | NA | 0.13 | 0.13 | 0.12 | 0.12 |
Pretax Income | NA | -1.99 | -1.69 | -1.87 | -2.24 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.99 | -1.69 | -1.87 | -2.24 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.99 | -1.69 | -1.87 | -2.24 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 3.37 | 3.34 | 3.34 | 3.34 |
Diluted EPS Before Non-Recurring Items | NA | -0.59 | -0.51 | -0.56 | -0.67 |
Diluted Net EPS (GAAP) | NA | -0.59 | -0.51 | -0.56 | -0.67 |